Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Common Equity (2020 - 2025)

Inhibikase Therapeutics (IKT) has disclosed Common Equity for 6 consecutive years, with $72.9 million as the latest value for Q3 2025.

  • Quarterly Common Equity rose 13839.08% to $72.9 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $72.9 million through Sep 2025, up 13839.08% year-over-year, with the annual reading at $94.9 million for FY2024, 764.16% up from the prior year.
  • Common Equity for Q3 2025 was $72.9 million at Inhibikase Therapeutics, down from $80.1 million in the prior quarter.
  • The five-year high for Common Equity was $94.9 million in Q4 2024, with the low at -$530591.0 in Q3 2024.
  • Average Common Equity over 5 years is $34.8 million, with a median of $25.3 million recorded in 2023.
  • The sharpest move saw Common Equity plummeted 103.53% in 2024, then soared 13839.08% in 2025.
  • Over 5 years, Common Equity stood at $38.4 million in 2021, then plummeted by 45.24% to $21.0 million in 2022, then plummeted by 47.81% to $11.0 million in 2023, then skyrocketed by 764.16% to $94.9 million in 2024, then dropped by 23.16% to $72.9 million in 2025.
  • According to Business Quant data, Common Equity over the past three periods came in at $72.9 million, $80.1 million, and $85.7 million for Q3 2025, Q2 2025, and Q1 2025 respectively.